Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of the Rheumatic Diseases

Topics

Medicine

Immunology

Pathology

Internal Medicine

Hematology

Show all topics

DOI

10.1136/annrheumdis-2018-213328

License

CC-BY-NC

Other Formats

PDF